Page 34 - IMO-1-1
P. 34
Innovative Medicines & Omics Antioxidant nanomedicines for therapies
A
B
Figure 21. Schematic illustration for the application of CeO nanoparticles in treating hepatic ischemia-reperfusion injury (A), as well as the underlying
2
325
biochemical mechanism (B). Reproduced with permission from Ni et al. Copyright © 2019, Wiley-VCH.
Table 6. Summary of representative antioxidant nanomedicines for the treatment of liver diseases
Antioxidant nanomedicine Reaction type Disease References
Bilirubin nanoparticle Non-catalytic Hepatic ischemia-reperfusion injury 322
All-trans retinoic acid-based nanoparticle Non-catalytic Hepatic ischemia-reperfusion injury 323
CeO nanoparticle Catalytic Hepatic ischemia-reperfusion injury 324, 325
2
SOD and catalase co-delivered nanoparticle Catalytic Hepatitis 332
Resveratrol-loading nanomicelle Non-catalytic Liver cirrhosis 41
Polydopamine nanoparticle Non-catalytic Liver cirrhosis 339
Abbreviation: SOD: Superoxide dismutase
Volume 1 Issue 1 (2024) 28 doi: 10.36922/imo.2527
